Clinical research lies at the heart of who we are. Baxter uses scientific evidence systematically, and transparently, to inform the development of new and state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Baxter.
The Clinical Benefits of HDx Therapy for Chronic HD Patients
The Nephrology Dialysis Transplantation (NDT) Journal has published results of two clinical studies comparing with Theranova dialyzer with the latest generation of high-flux dialyzers.Read More
A Focus on Clinical Research
Effects of medium cut-off (Theranova) dialyzer on hemodialysis patients: a prospective, crossover study - Cozzolino M et al.
Evaluation of Albumin Loss During Hemodialysis with Theranova® Medium Cut-Off (MCO) Dialyzer: Six Months Follow-Up - Marchionna et al.
Higher in vivo β2microglobulin clearance in expanded hemodialysis: preliminary results of a cross-over trial. - Cordeiro et al.
Intradialytic kinetics of middle molecules during hemodialysis and hemodiafiltration - Leypoldt et al.
Long term effects of expanded hemodialysis (HDx) on clinical and laboratory parameters in a large cohort of dialysis patients - Bunch et al.
Medium-Range Molecule Extraction and Intradialytic Hemodynamics: Comparison of Two Convective Dialysis Methods - Cordeiro et al
Multicenter, prospective, randomised, crossover trial to demonstrate the benefits of hemodialysis without acetate (with citrate): ABC-treat study - Sequera et al.
Quality of life reported by patients with expanded hemodialysis by the Theranova dialyzer in RTS Colombia - Sanabria et al.